On May 2, 2017 Ablynx announced that it has successfully completed patient recruitment in the multi-national, double-blind, placebo-controlled Phase III HERCULES study of caplacizumab to treat acquired TTP. If approved, this drug will be the first therapeutic specifically indicated for the disease.
The article published April 2017 in Nature Reviews Disease Primers will serve as reference resource for experienced researchers and a useful broad introduction to the field for early career researchers and medical students. Two of the five authors are researchers (
Today, events are occurring around the world to recognize rare diseases. What a great time for you to get involved in supporting a rare disease by making a difference. This year Rare Disease Day has created a theme around RESEARCH, with a slogan of 'With research, possibilities are limitless'.
Ablynx submits a marketing authorisation application to the European Medicines Agency for Caplacizumab, for the treatment of aTTP. If approved, it will be the first therapeutic specifically indicated for the treatment of aTTP.
What is the study about? In partnership with the National Organization for Rare Disorders, this will be the first large-scale study about the information and psychosocial support needs of people living with rare disorders in the US. The purpose of this research study is to assess these needs, from the perspectives of people with a variety of rare disorders, to find similarities and differences across disorders.